Exposure response modelling a safe and profitable way to speed drugs to market By Dr Gregory Fisher and Dr Arthur L. Craigmill The applicability of physiologically-based pharmacokinetic modelling (PBPK) far exceeds that of classical PK in predictive pharmacokinetics, tissue dosimetry, drug efficacy, and drug safety. This in silico technique, in conjunction with in vitro and […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!